Stoke Therapeutics (STOK) Other Accumulated Expenses (2018 - 2026)

Stoke Therapeutics' Other Accumulated Expenses history runs 9 years deep, the most recent figure standing at $1.5 million for Q1 2026.

• In Q1 2026, Other Accumulated Expenses fell 27.68% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $1.5 million (down 27.68% YoY), while the FY2025 annual figure was $1.1 million, up 40.77% from the prior year.
• Other Accumulated Expenses was $1.5 million for Q1 2026 at Stoke Therapeutics, up from $1.1 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $2.1 million in Q1 2025 to a low of $426000.0 in Q3 2022.
• Historically, Other Accumulated Expenses has averaged $899529.4 across 5 years, with a median of $753000.0 in 2024.
• The sharpest annual moves came in 2022 and 2026: Other Accumulated Expenses jumped 4900.0% in 2022, then decreased 27.68% in 2026.
• A 5-year view of Other Accumulated Expenses shows it stood at $509000.0 in 2022, then soared by 68.37% to $857000.0 in 2023, then dropped by 12.14% to $753000.0 in 2024, then surged by 40.77% to $1.1 million in 2025, then surged by 41.51% to $1.5 million in 2026.
• The last three Other Accumulated Expenses figures came in at $1.5 million (Q1 2026), $1.1 million (Q4 2025), and $795000.0 (Q3 2025), per Business Quant data.